当前位置: X-MOL 学术Ann. Lab. Med. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Platelet and Monocyte Microvesicles as Potential Biomarkers of COVID-19 Severity: A Cross-Sectional Analysis.
Annals of Laboratory Medicine ( IF 4.0 ) Pub Date : 2024-03-12 , DOI: 10.3343/alm.2023.0395
Nastasya Nunki 1, 2 , Yetti Hernaningsih 3 , Puspa Wardhani 3, 4, 5 , Asih Herawati 6 , Narazah Mohd Yusoff 3, 7 , Emmanuel Jairaj Moses 7, 8 , Bambang Pujo Semedi 9
Affiliation  

Background Coronavirus disease (COVID-19) induces inflammation, coagulopathy following platelet and monocyte activation, and fibrinolysis, resulting in elevated D-dimer levels. Activated platelets and monocytes produce microvesicles (MVs). We analyzed the differences in platelet and monocyte MV counts in mild, moderate, and severe COVID-19, as well as their correlation with D-dimer levels. Methods In this cross-sectional study, blood specimens were collected from 90 COVID-19 patients and analyzed for D-dimers using SYSMEX CS-2500. Platelet MVs (PMVs; PMVCD42b+ and PMVCD41a+), monocyte MVs (MMVs; MMVCD14+), and phosphatidylserine-binding annexin V (PS, AnnV+) were analyzed using a BD FACSCalibur instrument. Results PMV and MMV counts were significantly increased in COVID-19 patients. AnnV+ PMVCD42b+ and AnnV+ PMVCD41a+ cell counts were higher in patients with severe COVID-19 than in those with moderate clinical symptoms. The median (range) of AnnV+ PMVCD42b+ (MV/μL) in mild, moderate, and severe COVID-19 was 1,118.3 (328.1-1,910.5), 937.4 (311.4-2,909.5), and 1,298.8 (458.2-9,703.5), respectively (P =0.009). The median (range) for AnnV+ PMVCD41a+ (MV/μL) in mild, moderate, and severe disease was 885.5 (346.3-1,682.7), 663.5 (233.8-2,081.5), and 1,146.3 (333.3-10,296.6), respectively (P =0.007). D-dimer levels (ng/mL) weak correlated with AnnV+ PMVCD41a+ (P =0.047, r=0.258). Conclusions PMV PMVCD42b+ and PMVCD41a+ counts were significantly increased in patients with severe clinical symptoms, and PMVCD41a+ counts correlated with D-dimer levels. Therefore, MV counts can be used as a potential biomarker of COVID-19 severity.

中文翻译:


血小板和单核细胞微泡作为 COVID-19 严重程度的潜在生物标志物:横断面分析。



背景冠状病毒病 (COVID-19) 会诱发炎症、血小板和单核细胞活化后的凝血病以及纤维蛋白溶解,导致 D-二聚体水平升高。活化的血小板和单核细胞产生微泡(MV)。我们分析了轻度、中度和重度 COVID-19 中血小板和单核细胞 MV 计数的差异,以及它们与 D-二聚体水平的相关性。方法 在这项横断面研究中,收集了 90 名 COVID-19 患者的血液样本,并使用 SYSMEX CS-2500 分析了 D-二聚体。使用 BD FACSCalibur 仪器分析血小板 MV(PMV;PMVCD42b+ 和 PMVCD41a+)、单核细胞 MV(MMV;MMVCD14+)和磷脂酰丝氨酸结合膜联蛋白 V(PS、AnnV+)。结果 COVID-19 患者的 PMV 和 MMV 计数显着增加。重症 COVID-19 患者中的 AnnV+ PMVCD42b+ 和 AnnV+ PMVCD41a+ 细胞计数高于中度临床症状患者。轻度、中度和重度 COVID-19 中 AnnV+ PMVCD42b+ (MV/μL) 的中位数(范围)分别为 1,118.3 (328.1-1,910.5)、937.4 (311.4-2,909.5) 和 1,298.8 (458.2-9,703.5) (P = 0.009)。轻度、中度和重度疾病中 AnnV+ PMVCD41a+ (MV/μL) 的中位数(范围)分别为 885.5 (346.3-1,682.7)、663.5 (233.8-2,081.5) 和 1,146.3 (333.3-10,296.6) (P =0.007) 。 D-二聚体水平 (ng/mL) 与 AnnV+ PMVCD41a+ 弱相关(P =0.047,r=0.258)。结论 临床症状严重的患者PMV PMVCD42b+和PMVCD41a+计数显着升高,且PMVCD41a+计数与D-二聚体水平相关。因此,MV 计数可用作 COVID-19 严重程度的潜在生物标志物。
更新日期:2024-03-12
down
wechat
bug